| Trial ID: | L4558 |
| Source ID: | NCT02426541
|
| Associated Drug: |
Dapagliflozin
|
| Title: |
Effects of Dapagliflozin 10 mg on Insulin Resistance in Patients With Type 2 Diabetes Mellitus
|
| Acronym: |
DERISC
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT02426541/results
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: Dapagliflozin|DRUG: Placebo
|
| Outcome Measures: |
Primary: Adjusted Change From Baseline in Skeletal Muscle Insulin-stimulated Gluocose Uptake, Adjusted change from baseline in skeletal muscle insulin-stimulated gluocose uptake (umol/min/kg), From baseline to Week 8 | Secondary: Adjusted Change in Adipose Tissue Insulin-stimulated Glucose Uptake, Change in adipose tissue insulin-stimulated glucose uptake assessed by hyperglycemic-euglycemic clamp using F-FDG PET, Baseline to Week 8|Adjusted Change in Liver Insulin-stimulated Glucose Uptake From Baseline to Week 8, Adjusted change in liver insulin-stimulated glucose uptake assessed by hyperglycemic-euglycemic clamp using F-FDG PET, Baseline to Week 8
|
| Sponsor/Collaborators: |
Sponsor: AstraZeneca | Collaborators: Antaros Medical|Bioventure Hub|43183 Mölndal|Sweden
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
55
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2015-03-23
|
| Completion Date: |
2016-04-28
|
| Results First Posted: |
2018-02-05
|
| Last Update Posted: |
2018-02-05
|
| Locations: |
Research Site, Turku, Finland
|
| URL: |
https://clinicaltrials.gov/show/NCT02426541
|
